Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT01917331 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD

Start date: March 2014
Phase: Phase 3
Study type: Interventional

Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of Beclometasone+Formoterol+Glycopyrrolate (BDP/FF/GB) administered via pMDI over the equivalent dose of Foster® in COPD (Chronic Obstructive Pulmonary Disease) patients after 52 weeks of treatment

NCT ID: NCT01915784 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD

Start date: July 2013
Phase: Phase 3
Study type: Interventional

Preference study: Genuair® (Pressair™) vs Breezhaler® (Neohaler™) inhalers in patients with COPD

NCT ID: NCT01915511 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

IPF/ILD-PRO
Start date: June 2014
Phase:
Study type: Observational [Patient Registry]

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progressive phenotype, HRCT images will be collected throughout the study for use in future research efforts.

NCT ID: NCT01911364 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease

Start date: January 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the triple combination of beclometasone dipropionate+Formoterol fumarate+Glycopyrrolate bromide is effective for the treatment of severe COPD patients (chronic obstructive pulmonary disease)

NCT ID: NCT01909544 Recruiting - Clinical trials for Pulmonary Disease, Chronic Obstructive

Muscle Metabolism and Oxygenation During Localized Fatigue-exercise in COPD

Start date: September 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate whether a localized exercise, in which cardiorespiratory demand is reduced, will result in greater limb muscle fatigue in patients with COPD as a consequence of muscle oxygenation and muscle metabolism disturbances.

NCT ID: NCT01908140 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: September 2013
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)

NCT ID: NCT01906931 Completed - Clinical trials for Interstitial Lung Disease

Ambulatory Oxygen for ILD

Start date: August 2013
Phase: Phase 2
Study type: Interventional

People with interstitial lung disease (ILD) are frequently prescribed ambulatory oxygen, to increase oxygen levels in the blood during daily activities. The best way of delivering this type of oxygen has not been established. The aim of this study is to compare two devices for delivering oxygen in people with interstitial lung disease - the traditional method using portable cylinders and a newer method using a portable concentrator. The investigators hypothesise that oxygen levels during exercise will be significantly higher when using a portable cylinder, but this difference will be small.

NCT ID: NCT01905982 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

The Effect of Reflective Breathing Therapy Compared With Conventional Breathing Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) III-IV; part2

Start date: January 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether different types of breathing therapies in patients with COPD III-IV decrease dyspnea, increase activity and have impact on parasympathetic activities.

NCT ID: NCT01903850 Withdrawn - Clinical trials for Lung Diseases, Obstructive

TruFreeze™ Airway Obstruction: TAO STUDY

TAO
Start date: July 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to prospectively assess the efficacy and safety of spray cryotherapy ablation with the truFreeze System in conjunction with mechanical dilation or debridement for the treatment of clinically significant obstructions of the central airways. The primary effectiveness endpoint is the proportion of subjects with a minimum of 25% improvement in luminal patency following SCT treatment and mechanical intervention 30 days (+/- 5 days) following treatment. Additionally, a primary clinical safety endpoint is the reporting of all adverse events.

NCT ID: NCT01899742 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

Start date: September 15, 2014
Phase: Phase 3
Study type: Interventional

The primary objective is to compare the efficacy of UMEC/VI Inhalation Powder (62.5/25 mcg) once-daily with tiotropium (18 mcg) once-daily over 12 weeks for the treatment of subjects with COPD who have received tiotropium and continue to have symptoms while on tiotropium.